NRG2025 Summer Meeting Registration Now Open! | | |
Join us in Washington DC for the NRG2025 Summer Meeting. The meeting will be held in-person at the Marriott Marquis, July 24-26, 2025, with select virtual sessions being held July 16-25, 2025. Register soon to avoid the late registration fee!
More information | Agenda | Register
| | NRG Advanced Practice Provider (APP) Symposium at NRG2025 | | Calling all APPs! We are pleased to announce our NRG Oncology Advanced Practice Providers (APP) Symposium to be held during the NRG2025 Summer Meeting in Washington, DC on Friday, July 25, 2025, 8:15-9:45am ET. The session will also be available virtually. The goals for the session will be to identify the different roles that APPs can serve in NCI-sponsored research and elevate their involvement in clinical research at practice sites. The session chairs are Deb Bruner, Kathleen Castro, Christa Braun-Inglis, and Melyssa Foust. Please refer to the flyer for additional details. Register for the session via the NRG2025 Summer Meeting registration portal. | | |
Results of NRG-RTOG 9813 Comprehensive Molecular Analysis Demonstrates Importance of Using 2021-WHO Criteria when Classifying Histological Grade 3 Astrocytoma Patients
Results of a comprehensive molecular analysis of the NRG-RTOG 9813 data, a phase III study testing radiation (RT) and temozolomide (TMZ) versus RT and BCNU/CCNU in anaplastic astrocytoma were recently published in the International Journal of Radiation Oncology, Biology, Physics.
| NRG-BN013: A Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (fSRS) For Intact Brain Metastases | Watch our interview with Rupesh Kotecha, MD, NRG-BN013 Principal Investigator, as he discusses this Phase III study of single fraction stereotactic radiosurgery (SRS) versus fractionated SRS (fSRS) for intact brain metastases. | |
The NRG Oncology Podcast - New Episodes!
Listen on Apple Podcasts, Spotify, Amazon/Audible, and YouTube.
| | |
Less Radical Podcast
In case you missed it, a podcast series that is part of the Cancer History Project, Less Radical, highlights the story of Dr. Bernie Fisher, who revolutionized the treatment for breast cancer and transformed today’s understanding of all cancers. Check it out here.
| | | NRG Study News & New Protocols Under Development | | New Protocols Under Development | | NRG Oncology Activates the PREEMPT Trial for Patients with High-Risk Bone Asymptomatic Metastases (NRG-CC014) | | NRG Oncology recently activated NRG-CC014, a pragmatic multicenter randomized phase 3 clinical trial, also known as the “PREEMPT” study. This trial is currently enrolling patients with high-risk bone metastases that are asymptomatic. The trial will compare the effects of adding radiation therapy to the usual care on the occurrence of bone-related complications (such as spinal cord compression, fracture, and surgery for instability) in this patient population. | |
REGISTER Today: The NRG-CC014 Study (PREEMPT) Webinar
Join the webinar on June 16, 2025, 2-3pm ET, to learn more about the NRG-CC014 (PREEMPT) trial. Please see the flyer for details and register in advance for the webinar. After registering, you will receive an email with the program link.
| | | Margin Width and Local Recurrence in the NRG-NSABP B-35 DCIS Lumpectomy Trial | | Dr. Irene Wapnir recently presented the results of the NRG-NSABP B-35 trial at the American Society of Breast Surgeons Annual Meeting in Las Vegas. The results indicated that repeat lumpectomy surgeries to achieve wider disease-free tumor margins may be reconsidered for certain women being treated for ductal cancer in situ (DCIS), the earliest stage of breast cancer. | |
REGISTER TODAY: The NRG-GU012 Study (SAMURAI) Webinar
The NRG-GU012 “SAMURAI” Study Principal Investigators will be hosting a webinar to discuss the trial and accept any questions regarding the study from sites. This webinar will be held on Friday, June 13, 2025 from 12:00-1:00pm ET / 9:00-10:00am PT. NRG-GU012 is a Phase II study of stereotactic ablative radiation therapy (SABR) for patients with unresected renal cell carcinoma receiving immunotherapy.
Register here.
| | Protocol Support Committee (PSC) Column | | |
Written by Michele Harmon, RN, BSN; Administrator, Southeast Clinical Oncology Research Consortium; SCOR, NCORP
The World Health Organization (WHO) defined health as “a state of complete physical, mental, and social well-being and not merely the absence of disease or infirmity.” This definition is from 1948. In oncology, we care for the health of our patients. Part of health care delivery is to focus on how treatments alter the quality of life for our patients. Is this important information? It did not used to be discussed.
| | Leadership Changes in Protocol Support Committee (PSC) and PSC Subcommittees | | NRG Oncology (NRG) recently announced several transitions in the organization’s Protocol Support Committee (PSC) as well as the subcommittees within the PSC umbrella. | | |
Advocate Angle
More Than Medicine: Why Cancer Research Needs Every Voice
Written by Marlyn Molero Sanchez, Vice Chair, NRG Oncology Patient Advocate Committee
| | |
Each May, we celebrate National Cancer Research Month, honoring the scientific breakthroughs that bring hope to patients, families, and communities impacted by cancer. But this month is also about something just as powerful: the people behind the research. The patients. The caregivers. The communities. The voices that are too often unheard.
| |
NRG Oncology Veterans Affairs – Military Treatment Facility Subcommittee
Written by Vlad C. Sandulache MD, PhD and Maria Kelly MD
May 2025 marks 100 years of history for research efforts in the U.S. Department of Veterans Affairs, focused on those who have sacrificed life and limb in the service of their country. NRG Oncology reformed a VA-MTF Subcommittee in the spring of 2022, in order to increase focus on patients with locally advanced malignancies including genitourinary, lung, head and neck and gastrointestinal.
| | Introducing the NRG Oncology Investigator & Career Development Committee | | Recently, NRG Oncology (NRG) reorganized and refocused its committee structure to better engage our early career researchers and provide greater support to investigators at all career stages. This initiative led to the creation of the Investigator & Career Development Committee which houses the Early Career Mentorship Subcommittee and the Investigator Development Subcommittee. These groups will expand upon the goals and efforts of the former Early Career and New Investigators Committee and Access and Opportunity Committees. | | |
An Update on the NRG Health Care Access Fellowship
NRG Oncology’s (NRG) National Community Oncology Research Program (NCORP) provides mentorship and training for new/early career investigators. In the last four years, nine Health Care Access fellowships have been awarded, and we are approaching our fifth year of selecting fellows for the next award period in 2026. The program trains selected early-stage investigators in the NRG system by means of a structured mentorship experience.
| | |
Join this FORTE Webinar on Microsoft Teams to learn about polyp types for FORTE eligibility requirements from Protocol Co-Chair, Dr. Jeffrey Dueker.
Tuesday, May 20, 2025 / 2 pm ET Register today!
| FORTE Veterans Administration Site Call – May 28, 2025 | We look forward to discussing FORTE topics at the next FORTE Veterans Administration Site Call. These will include but are not limited to - screening tools, VisionTree, sample collection. This webinar will address VA-specific subjects; all VA sites are recommended to attend both the FORTE Site Call and FORTE Veterans Administration Site Call. Wednesday, May 28, 2025; 3pm ET Register today! | | NRG Oncology has recently added Bluesky to our portfolio of social media platforms. If you are currently on Bluesky, follow us at @nrgonc.bsky.social. | | | | | |
